Clinical Study of ASN-3186 in Patients with Advanced Solid Tumors

Summary

This is a Phase I/IIa, open-label, multi-center, dose-escalation, and expansion study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of ASN-3186 when given orally in subjects with advanced solid tumors

Timeline

Start

2025-02-20

Primary completion

2029-03-20

Completion

2029-09-20

Drugs

Indications